Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William C Olson

Showing results (11-20 of 73) with videos related to

Pageof 8
Sort By:
Journal of Proteome Research|October 3, 2018
Multiplex Immuno-Liquid Chromatography-Mass Spectrometry-Parallel Reaction Monitoring (LC-MS-PRM) Quantitation of CD8A, CD4, LAG3, PD1, PD-L1, and PD-L2 in Frozen Human TissuesQian Zhang, Robert Salzler, Anthony Dore, et al.
Journal of Virology|April 30, 2003
Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirionsJames M Binley, Charmagne S Cayanan, Cheryl Wiley, et al.
The Prostate|November 21, 2015
Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancerVincent A DiPippo, Holly M Nguyen, Lisha G Brown, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 8, 2003
In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infectionSeth H Pincus, Hua Fang, Royce A Wilkinson, et al.
The Prostate|October 21, 2014
Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenograftsVincent A DiPippo, William C Olson, Holly M Nguyen, et al.
The Prostate|October 21, 2014
Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancerJose D Murga, Sameer M Moorji, Amy Q Han, et al.
Plos One|August 1, 2012
Protection against high-dose highly pathogenic mucosal SIV challenge at very low serum neutralizing titers of the antibody-like molecule CD4-IgG2Pascal Poignard, Brian Moldt, Karla Maloveste, et al.
Plos One|October 17, 2012
Succession in the gut microbiome following antibiotic and antibody therapies for Clostridium difficileGregory L Peterfreund, Lee E Vandivier, Rohini Sinha, et al.
Journal of Virology|March 14, 2003
The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype CTonie Cilliers, Jabulani Nhlapo, Mia Coetzer, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 17, 2004
L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virusEmmanuel G Cormier, Robert J Durso, Fotini Tsamis, et al.
Pageof 8

Showing results (11-20 of 73) with videos related to

Sort By:
Pageof 8
Journal of Proteome Research|October 3, 2018
Multiplex Immuno-Liquid Chromatography-Mass Spectrometry-Parallel Reaction Monitoring (LC-MS-PRM) Quantitation of CD8A, CD4, LAG3, PD1, PD-L1, and PD-L2 in Frozen Human TissuesQian Zhang, Robert Salzler, Anthony Dore, et al.
Journal of Virology|April 30, 2003
Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirionsJames M Binley, Charmagne S Cayanan, Cheryl Wiley, et al.
The Prostate|November 21, 2015
Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancerVincent A DiPippo, Holly M Nguyen, Lisha G Brown, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 8, 2003
In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infectionSeth H Pincus, Hua Fang, Royce A Wilkinson, et al.
The Prostate|October 21, 2014
Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenograftsVincent A DiPippo, William C Olson, Holly M Nguyen, et al.
The Prostate|October 21, 2014
Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancerJose D Murga, Sameer M Moorji, Amy Q Han, et al.
Plos One|August 1, 2012
Protection against high-dose highly pathogenic mucosal SIV challenge at very low serum neutralizing titers of the antibody-like molecule CD4-IgG2Pascal Poignard, Brian Moldt, Karla Maloveste, et al.
Plos One|October 17, 2012
Succession in the gut microbiome following antibiotic and antibody therapies for Clostridium difficileGregory L Peterfreund, Lee E Vandivier, Rohini Sinha, et al.
Journal of Virology|March 14, 2003
The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype CTonie Cilliers, Jabulani Nhlapo, Mia Coetzer, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 17, 2004
L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virusEmmanuel G Cormier, Robert J Durso, Fotini Tsamis, et al.
Pageof 8